marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-05-2024
CRISPR Therapeutics AG Balance Sheet 2011-2024 | CRSP
Annual Balance Sheet CRISPR Therapeutics AG
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-151 M | 32.1 M | -698 M | - | -891 M | -457 M | -240 M | -316 M | -118 M | -945 K | - | - | - |
Long Term Debt |
223 M | 228 M | 213 M | - | - | - | - | - | 38.3 M | - | - | - | - |
Long Term Debt Current |
15.6 M | 15.8 M | 12.2 M | 11.4 M | 8.49 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 70.2 M | 69.1 M | 69 M | 90.1 M | 178 M | 6.36 M | - | - | - |
Total Current Liabilities |
109 M | 121 M | 120 M | 94.3 M | 57.1 M | 27.7 M | 14.5 M | 22 M | - | - | - | - | - |
Total Liabilities |
347 M | 368 M | 352 M | 164 M | 127 M | 96.8 M | 83.5 M | 112 M | 189 M | 8.5 M | - | - | - |
Deferred Revenue |
4.1 M | - | 1.01 M | 2.34 M | 960 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-1 B | -846 M | -196 M | -574 M | -225 M | -292 M | -125 M | -57.1 M | -33.9 M | -8.4 M | - | - | - |
Total Assets |
2.23 B | 2.24 B | 2.75 B | 1.83 B | 1.07 B | 489 M | 271 M | 345 M | 159 M | 1.53 M | - | - | - |
Cash and Cash Equivalents |
389 M | 212 M | 923 M | 1.17 B | 944 M | 457 M | 240 M | 316 M | 156 M | 945 K | - | - | - |
Book Value |
1.88 B | 1.88 B | 2.4 B | 1.66 B | 939 M | 392 M | 188 M | 233 M | -29.1 M | -6.97 M | - | - | - |
Total Shareholders Equity |
1.88 B | 1.88 B | 2.4 B | 1.66 B | 939 M | 392 M | 188 M | 233 M | -29.1 M | -6.97 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet CRISPR Therapeutics AG
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
211 M | 215 M | 219 M | 223 M | 227 M | 230 M | 225 M | 228 M | 231 M | 234 M | 228 M | 213 M | 193 M | 175 M | 49.4 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 44 M | 44 M | 44 M | 44 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
316 M | 359 M | 355 M | 347 M | 359 M | 381 M | 389 M | 368 M | 399 M | 373 M | 361 M | 352 M | 309 M | 296 M | 152 M | 164 M | 164 M | 164 M | 164 M | 127 M | 127 M | 127 M | 127 M | 96.8 M | 96.8 M | 96.8 M | 96.8 M | 83.5 M | 83.5 M | 83.5 M | 83.5 M | 112 M | 112 M | 112 M | 112 M | 124 M | 124 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
4.48 M | 4.76 M | 4.07 M | 4.1 M | 3.5 M | - | - | - | - | - | - | 1.01 M | 1.56 M | 2.07 M | 1.8 M | 2.34 M | 2.34 M | 2.34 M | 2.34 M | 960 K | 960 K | 960 K | 960 K | 102 K | 102 K | - | - | - | - | - | - | - | 63.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.33 B | -1.24 B | -1.12 B | -1 B | -1.09 B | -977 M | -899 M | -846 M | -736 M | -561 M | -375 M | -196 M | -54.7 M | 72.5 M | -687 M | -574 M | -574 M | -574 M | -574 M | -225 M | -225 M | -225 M | -225 M | -292 M | -292 M | -292 M | -292 M | -125 M | -125 M | -125 M | -125 M | -57.1 M | -57.1 M | -57.1 M | -57.1 M | -33.9 M | -33.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.26 B | 2.34 B | 2.44 B | 2.23 B | 2.09 B | 2.2 B | 2.24 B | 2.24 B | 2.35 B | 2.46 B | 2.61 B | 2.75 B | 2.82 B | 2.9 B | 1.96 B | 1.83 B | 1.83 B | 1.83 B | 1.83 B | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 489 M | 489 M | 489 M | 489 M | 271 M | 271 M | 271 M | 271 M | 345 M | 345 M | 345 M | 345 M | 159 M | 159 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
226 M | 484 M | 707 M | 389 M | 528 M | 445 M | 344 M | 212 M | 494 M | 497 M | 684 M | 923 M | 1.01 B | 1.65 B | 1.13 B | 1.17 B | 1.17 B | 1.17 B | 1.17 B | 944 M | 944 M | 944 M | 944 M | 457 M | 457 M | 457 M | 457 M | 240 M | 254 M | 272 M | 289 M | 316 M | 316 M | 316 M | 316 M | 156 M | 156 M | - | - | 945 K | - | - | - | 361 K | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.94 B | 1.98 B | 2.08 B | 1.88 B | 1.73 B | 1.82 B | 1.85 B | 1.88 B | 1.95 B | 2.09 B | 2.24 B | 2.4 B | 2.51 B | 2.6 B | 1.81 B | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 939 M | 939 M | 939 M | 939 M | 392 M | 392 M | 392 M | 392 M | 188 M | 188 M | 188 M | 188 M | 233 M | 233 M | 233 M | 233 M | 35.4 M | 35.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.94 B | 1.98 B | 2.08 B | 1.88 B | 1.73 B | 1.82 B | 1.85 B | 1.88 B | 1.95 B | 2.09 B | 2.24 B | 2.4 B | 2.51 B | 2.6 B | 1.81 B | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 939 M | 939 M | 939 M | 939 M | 392 M | 392 M | 392 M | 392 M | 188 M | 188 M | 188 M | 188 M | 233 M | 233 M | 233 M | 233 M | -29.1 M | -29.1 M | - | - | -6.97 M | - | - | - | -581 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency